OS Therapies Inc (OSTX)
$1.65+$0.01 (+0.61%) TodayExtended Hours
OS Therapies Inc is a clinical stage biopharmaceutical company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. The company's mission is to address the need for new treatments in cancers of the bone in children and young adults. The company has pipeline of product candidates targeting multiple indications for solid cancers including two drug technologies: (i) OST-HER2, an off-the-shelf immunotherapy, which is a type of cancer treatment that helps the immune system fight cancer and OST-tADC which is a tunable drug conjugate (tADC) platform currently in preclinical development. Each tADC contains four main components: ligand, payload cassette adaptor, linker and payload.
No Form 4 activity for OSTX in the last 90 days.
16 Form 4 filings on record, the earliest from Dec 19, 2025, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Avril Suzette McKean-Dieser - Director | Grant or award | Stock options (right to buy) | 50,000 | $0.00 | - | |
| Theodore F. Search - Director | Grant or award | Stock options (right to buy) | 50,000 | $0.00 | - | |
| John Ciccio - Director | Grant or award | Stock options (right to buy) | 50,000 | $0.00 | - | |
| Christopher P. Acevedo - Officer | Grant or award | Stock options (right to buy) | 100,000 | $0.00 | - | |
| Robert Petit - Officer | Grant or award | Stock options (right to buy) | 100,000 | $0.00 | - | |
| Olivier Roger Jarry - Director | Grant or award | Stock options (right to buy) | 50,000 | $0.00 | - | |
| Karim Galzahr - Director | Grant or award | Stock options (right to buy) | 50,000 | $0.00 | - | |
| Paul A. Romness - Officer | Grant or award | Stock options (right to buy) | 1,000,000 | $0.00 | - | |
| Theodore F. Search - Director | Grant or award | Stock options (right to buy) | 140,000 | $0.00 | - | |
| Robert Petit - Officer | Grant or award | Stock options (right to buy) | 500,000 | $0.00 | - | |
| Paul A. Romness - Officer | Grant or award | Stock options (right to buy) | 1,950,000 | $0.00 | - | |
| Olivier Roger Jarry - Director | Grant or award | Stock options (right to buy) | 140,000 | $0.00 | - | |
| Karim Galzahr - Director | Grant or award | Stock options (right to buy) | 140,000 | $0.00 | - | |
| John Ciccio - Director | Grant or award | Stock options (right to buy) | 140,000 | $0.00 | - | |
| Christopher P. Acevedo - Officer | Grant or award | Stock options (right to buy) | 200,000 | $0.00 | - | |
| Avril Suzette McKean-Dieser - Director | Grant or award | Stock options (right to buy) | 140,000 | $0.00 | - |
OS Therapies Inc (OSTX) has filed no insider reports in the last 90 days. The most recent on record is dated 2026-02-13. The full record for OSTX runs to 16 Form 4 filings, the earliest from 2025-12-19. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of OSTX were filed in the last 90 days.
No insider sales of OSTX were filed in the last 90 days.
This page tracks OSTX Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add OSTX to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
$OTAIStarlink AI Acquisition Corp
$OTFBlue Owl Technology Finance Corp.
$OTLYOatly Group AB
$OVIDOvid Therapeutics Inc.
$OWLCXBlue Owl Alternative Credit Fund
$OWLSOBOOK HOLDINGS INC.
$OWPCOne World Products, Inc.
$OXLCOxford Lane Capital Corp.
$OXSQOxford Square Capital Corp.
$OZSCOZOP ENERGY SOLUTIONS, INC.Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.